shekhara370@gmail.com
Phone : +919336504033
Cancer treatment continues to develop with therapies designed to target cancer cells and support the body's natural defence mechanisms. Immunotherapy for Cancer in Gurugram Sector 7 is an important treatment option for selected patients, helping the immune system recognise and attack cancer cells. It offers an additional approach to cancer care, either as a standalone treatment or alongside chemotherapy, radiation therapy, surgery, or targeted medicines.
Immunotherapy is not suitable for every type of cancer or every patient. Its effectiveness depends on the cancer diagnosis, tumour characteristics, previous treatments, and overall health. Consulting a qualified oncology specialist helps patients understand whether immunotherapy is appropriate and what benefits and risks to expect.
The immune system protects the body against infections and abnormal cells. However, some cancer cells develop ways to avoid immune detection or reduce the immune system's ability to attack them.
Immunotherapy uses medicines or other biological approaches to help the immune system recognise and respond to cancer. Unlike conventional chemotherapy, which directly affects rapidly dividing cells, many immunotherapies work by changing how immune cells interact with cancer.
The treatment response varies between individuals. Some patients experience substantial benefits, while others do not respond or develop side effects that require medical attention.
An oncologist reviews medical reports, biopsy findings, imaging scans, and relevant biomarker results before recommending this treatment.
Different immunotherapy approaches work through different mechanisms. The appropriate option depends on the cancer type and the patient's clinical profile.
Immune checkpoint inhibitors block certain proteins that cancer cells use to reduce immune activity. These medicines help immune cells recognise and attack cancer cells more effectively.
They are used for selected cancers, including certain lung cancers, melanomas, kidney cancers, and other tumours. Their suitability often depends on clinical factors and biomarker testing.
Monoclonal antibodies are laboratory-produced proteins designed to recognise particular targets. Some antibodies help the immune system identify cancer cells, while others interfere with signals that support tumour growth.
Their role depends on the specific medicine and cancer diagnosis. Some antibody treatments are classified as targeted therapy rather than immunotherapy, although these categories can overlap.
CAR T-cell therapy modifies a patient's T cells to recognise specific cancer targets. The modified cells are then returned to the patient under specialist supervision.
This approach is used for certain blood cancers and requires specialised facilities and careful monitoring.
Some therapeutic cancer vaccines and immune-based treatments aim to stimulate a targeted immune response. Their availability and role depend on the cancer type and approved treatment indications.
The oncology team explains which approaches are relevant to the patient's diagnosis.
Immunotherapy is used in the management of selected cancers. These include:
Lung cancer: Certain patients receive immunotherapy alone or with chemotherapy.
Melanoma: Immune checkpoint inhibitors are important treatment options for appropriate cases.
Kidney cancer: Immunotherapy forms part of selected treatment plans, sometimes in combination with targeted medicines.
Bladder cancer: Specific immunotherapies are used in certain disease settings.
Lymphoma: Particular immune-based treatments are available for selected lymphoma types.
Other solid tumours: Treatment suitability depends on tumour characteristics, biomarkers, stage, and established clinical recommendations.
Some cancers respond better to immunotherapy than others. The specialist determines whether evidence supports its use in an individual case.
Biomarker testing helps identify characteristics that influence treatment decisions. Depending on the cancer, tests might examine PD-L1 expression, microsatellite instability, mismatch repair status, or other molecular features.
These results help oncologists determine whether a particular immunotherapy is appropriate. However, a biomarker result does not guarantee a successful response, and some treatments remain suitable for selected patients without a specific marker.
Patients should discuss the purpose of recommended tests and how the results might affect their treatment choices.
Immunotherapy has a different side-effect profile from many conventional cancer treatments. Some patients experience fatigue, skin rashes, diarrhoea, nausea, or changes in appetite.
Because immunotherapy activates immune responses, it sometimes causes inflammation in healthy organs. These immune-related effects might affect the lungs, liver, intestines, thyroid, or other body systems. Some complications become serious without prompt treatment.
Patients should report new symptoms to their oncology team immediately. Severe breathing difficulties, significant diarrhoea, chest pain, confusion, or other serious symptoms require urgent medical assessment.
Patients should not begin steroids, supplements, or other medicines to manage suspected side effects without medical guidance. Early recognition and appropriate treatment help reduce the risk of complications.
Selecting an oncology centre involves evaluating the specialist's experience, diagnostic services, treatment facilities, and follow-up arrangements.
Patients should consider the following points:
Qualifications and experience of the treating oncologist.
Availability of appropriate biomarker and molecular testing.
Access to the recommended immunotherapy medicines.
Facilities for monitoring treatment response and side effects.
Coordination with other cancer specialists.
Clear discussions about treatment costs, duration, and alternatives.
Patients should ask whether immunotherapy is an established treatment for their specific diagnosis and understand its potential benefits and limitations.
Immunotherapy requires regular monitoring to assess treatment response and identify complications. The oncology team might recommend blood tests, imaging scans, physical examinations, or additional investigations according to the treatment plan.
Treatment duration varies by medicine, cancer type, response, and side effects. Some patients receive immunotherapy for a defined period, while others require changes to their treatment plan.
Consulting a specialist for Immunotherapy for Cancer in Gurugram Sector 7 helps patients explore suitable options, understand biomarker testing, and receive guidance throughout treatment. A personalised approach supports informed decisions and coordinated cancer care.
No. Its suitability depends on the cancer type, stage, tumour characteristics, previous treatments, and the patient's general health.
Hair loss is not a typical effect of all immunotherapies, although it occurs with certain treatments or in combination with chemotherapy. Side effects vary by medicine.
Doctors assess symptoms, physical findings, imaging scans, blood tests, and other relevant investigations to evaluate the treatment response.
Dr Shekhar Anand | Medical Oncologist.All Rights Reserved © 2026